Soria, J. C.; Fülöp, A. 
; Maciel, Carlos Dias ; Fischer, J. R.; Girotto, G.; Lago, S; Smith, E; Ostoros, G.; Eberhardt, W. E. E.; Lishkovska, P; Lovick, S.; Mariani, G.; McKeown, A; Kilgour, E; Smith, P; Bowen. K; Kohlmann, A; Carlile, D. J.; Jänne. P. A.
Fonte: Annals of Oncology. Unidade: EESC
Assuntos: ONCOLOGIA, NEOPLASIAS PULMONARES, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SORIA, J. C. et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology, v. 28, n. 12, p. 3028-3036, 2017Tradução . . Disponível em: http://dx.doi.org/10.1093/annonc/mdx628. Acesso em: 10 jun. 2024.APA
Soria, J. C., Fülöp, A., Maciel, C. D., Fischer, J. R., Girotto, G., Lago, S., et al. (2017). SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology, 28( 12), 3028-3036. doi:10.1093/annonc/mdx628NLM
Soria JC, Fülöp A, Maciel CD, Fischer JR, Girotto G, Lago S, Smith E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen. K, Kohlmann A, Carlile DJ, Jänne. P. A. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer [Internet]. Annals of Oncology. 2017 ; 28( 12): 3028-3036.[citado 2024 jun. 10 ] Available from: http://dx.doi.org/10.1093/annonc/mdx628Vancouver
Soria JC, Fülöp A, Maciel CD, Fischer JR, Girotto G, Lago S, Smith E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen. K, Kohlmann A, Carlile DJ, Jänne. P. A. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer [Internet]. Annals of Oncology. 2017 ; 28( 12): 3028-3036.[citado 2024 jun. 10 ] Available from: http://dx.doi.org/10.1093/annonc/mdx628
